Market Cap (In USD)
447.56 Million
Revenue (In USD)
-
Net Income (In USD)
-125.04 Million
Avg. Volume
1.65 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.64-3.45
- PE
- -2.29
- EPS
- -0.69
- Beta Value
- 1.161
- ISIN
- US29479A1088
- CUSIP
- 29479A108
- CIK
- 1761918
- Shares
- 283266000.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Jonathan E. Lim M.D.
- Employee Count
- -
- Website
- https://www.erasca.com
- Ipo Date
- 2021-07-16
- Details
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
More Stocks
-
RMIOF
-
8963
-
JMPLFJohnson Matthey Plc
JMPLF
-
SOSSOS Limited
SOS
-
PUKPFPrudential plc
PUKPF
-
AMPAMP Limited
AMP
-
ELE
-
ILPT